Evidence map›Paper›PMID 41081985›Full record

ArticleEJNMMI radiopharmacy and chemistry2025

PET imaging of mitochondrial complex-I in the adenine-induced tubulointerstitial nephropathy mouse model using [

Kenneth Dahl, Peter Johnström, Miklós Toth, Vasco C Sousa, Charlotte Ericsson, Maria Strömstedt, Tord Inghardt, Miguel A Cortés González, Anna Reznichenko, Aurelija Jucaite and 7 more

Abstract read
In one paragraph

Article in EJNMMI radiopharmacy and chemistry, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

17 authors.

Kenneth DahlPET Science Centre, Precision Medicine and Biosamples, Oncology R&D, AstraZeneca, Karolinska Institutet, Stockholm, Sweden. kenneth.dahl@astrazeneca.com.
Peter JohnströmPET Science Centre, Precision Medicine and Biosamples, Oncology R&D, AstraZeneca, Karolinska Institutet, Stockholm, Sweden.
Miklós TothDepartment of Clinical Neuroscience, Centre for Psychiatry Research, Karolinska Institutet and Stockholm County Council, Stockholm, Sweden.
Vasco C SousaDivision of Imaging Core Facilities, Department of Clinical Neuroscience, Center for Imaging Research, Karolinska Institutet, Stockholm, Sweden.
Charlotte EricssonBioscience, Early Cardiovascular, Renal and Metabolism, Biopharma R&D, AstraZeneca, Gothenburg, Sweden.
Maria StrömstedtBioscience, Early Cardiovascular, Renal and Metabolism, Biopharma R&D, AstraZeneca, Gothenburg, Sweden.
Tord InghardtChemistry, Early Cardiovascular, Renal and Metabolism, Biopharma R&D, AstraZeneca, Gothenburg, Sweden.
Miguel A Cortés GonzálezDepartment of Clinical Neuroscience, Centre for Psychiatry Research, Karolinska Institutet and Stockholm County Council, Stockholm, Sweden.
Anna ReznichenkoTranslational Science and Experimental Medicine, Early Cardiovascular, Renal and Metabolism, Biopharma R&D, AstraZeneca, Gothenburg, Sweden.
Aurelija JucaitePET Science Centre, Precision Medicine and Biosamples, Oncology R&D, AstraZeneca, Karolinska Institutet, Stockholm, Sweden.
Zsolt CselényiPET Science Centre, Precision Medicine and Biosamples, Oncology R&D, AstraZeneca, Karolinska Institutet, Stockholm, Sweden.
Robert UnwinEarly Clinical Development, Early Cardiovascular, Renal and Metabolism, Biopharma R&D, AstraZeneca, Cambridge, UK.
Hiroyuki OhbaCentral Research Laboratory, Hamamatsu Photonics K. K., Hamamatsu, Japan.
Christer HalldinDepartment of Clinical Neuroscience, Centre for Psychiatry Research, Karolinska Institutet and Stockholm County Council, Stockholm, Sweden.
Benjamin ChallisEarly Clinical Development, Early Cardiovascular, Renal and Metabolism, Biopharma R&D, AstraZeneca, Cambridge, UK.
Hideo TsukadaCentral Research Laboratory, Hamamatsu Photonics K. K., Hamamatsu, Japan.
Magnus SchouPET Science Centre, Precision Medicine and Biosamples, Oncology R&D, AstraZeneca, Karolinska Institutet, Stockholm, Sweden.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

backgroundChronic kidney disease (CKD) poses a significant global health burden with limited effective treatments for its prevention, progression, and associated complications. Mitochondrial dysfunction is recognized as a pivotal factor in the development of kidney diseases, with mitochondrial complex-I (MC-I) playing a crucial role in assessing overall mitochondrial function. Recent advancements in selective MC-I positron emission tomography (PET) radioligands now allow for non-invasive visualization and quantification of renal mitochondrial status in vivo. The aim of the present study was to evaluate the utility of [

resultsBinding of the MC-I targeted PET radioligand, [

conclusionsAltogether, the findings suggest that [

Indexed as

Kidney diseaseMC-IPositron emission tomographyRadiopharmaceutical

Identifiers

PMID41081985
PMCPMC12518723

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.